Navigation Links
Actinium Pharmaceuticals Announces 2013 Annual Shareholder Meeting
Date:12/3/2013

NEW YORK, Dec. 3, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTCQB: ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that it will hold its Annual Shareholders' Meeting (the "Meeting") on Monday, December 23, 2013 at 9:30 AM ET at the Sheraton Mahwah, 1 International Boulevard, Mahwah, NJ.

The Meeting will include an introduction, adjournment and Company overview provided by Kaushik J. Dave, President and Chief Executive Officer of Actinium.

The Proxy Statement, with the accompanying Notice of Annual Meeting, and 2012 Annual Report on Form 10–K are available on the "Investors" section of the Company's website at http://www.actiniumpharmaceuticals.com.

Shareholders of record of the Company's common stock at the close of business on November 7, 2013 will be entitled to receive notice of and to vote on matters discussed at the Meeting.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. (OTCQB: ATNM.OB), is a New York based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers.  Actinium's targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha emitting actinium-225 and bismuth-213 radiopharmaceuticals in conjunction with monoclonal antibodies.  The Company also develops other radiopharmaceuticals for select applications.

For more information:

Visit our web site www.actiniumpharmaceuticals.com

Contacts:

Media:
Dennis S. Dobson Jr.
Tel: (203) 258-0159
Email: dennisdobsonjr@dobsonmediagroup.com  

Actinium Pharmaceuticals, Inc.
Investor/Media Relations: Corey Sohmer, (646) 459-4201
Email: csohmer@actiniumpharmaceuticals.com

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.

This news release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.


'/>"/>
SOURCE Actinium Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Actinium Pharmaceuticals Acute Myeloid Leukemia Clinical Data to be Presented Today at 8th International Symposium on Targeted Alpha Therapy Conference
2. MD Anderson Cancer Center joins Actinium Pharmaceuticals (API) Multicenter Actimab-A Trial
3. Avanir Pharmaceuticals to Participate in Two Conferences in December
4. Jazz Pharmaceuticals Announces Participation at the Piper Jaffray Healthcare Conference on December 3
5. RXi Pharmaceuticals Reports Financial Results for the Third Quarter of 2013
6. RXi Pharmaceuticals Announces the Start of Their First Phase 2 Study with RXI-109 for Treatment of Hypertrophic Scars in Conjunction with Scar Revision Surgery
7. UCLA Venture Capital Fund Selects KYTHERA Biopharmaceuticals CEO Keith Leonard for First Annual Entrepreneurial Achievement Award
8. SignalRX Pharmaceuticals Issued U.S. Patent Covering Novel Kinase Inhibitors For Treating Cancer and Other Diseases
9. GW Pharmaceuticals Commences Phase 1b/2a Clinical Trial for the Treatment of Glioblastoma Multiforme (GBM)
10. IPO, Earnings & Corporate Developments: Twitter, Vale SA, OCZ Technology Group, Radian Group, Keryx Biopharmaceuticals
11. Amgen and Onyx Pharmaceuticals Announce Upcoming Data Presentations at 55th American Society of Hematology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2017)... Princeton, NJ (PRWEB) , ... June 19, 2017 ... ... delivering innovative solutions for clinical development reported today that it is launching two ... Lake. The company will be demonstrating new capabilities at the DIA 2017 Annual ...
(Date:6/16/2017)... Boston, Massachusetts (PRWEB) , ... June 16, 2017 ... ... Big Data management and analytics solutions, today announced that its Anzo Smart Data ... Analytics and Semantic Technology Solution’ category for the 2017 Software & Information Industry ...
(Date:6/15/2017)... ... June 15, 2017 , ... The ... an artist’s journey through creative experimentation and interdisciplinary collaboration. Feature Creep, a solo ... 22nd. An opening reception will be held at EKG, located at 3600 Market ...
(Date:6/14/2017)... ... June 14, 2017 , ... ... discuss the initiative steered by the executive search firm, “Building Value in Precision ... Board of Directors of Foundation Medicine, led an open discussion with expert panelists ...
Breaking Biology Technology:
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market ... Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast ... from USD 14.30 Billion in 2017 to USD 31.75 Billion by 2022, ... ... MarketsandMarkets Logo ...
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ... appointment of independent Directors Mr. Robin D. Richards ... Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive ... their guidance and benefiting from their considerable expertise as we ...
(Date:4/5/2017)... 2017 KEY FINDINGS The global ... a CAGR of 25.76% during the forecast period of ... factor for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is ... geography. The stem cell market of the product is ...
Breaking Biology News(10 mins):